Shaperon

Shaperon AAQS

The The AAQS of Shaperon (378800.KQ) as of Oct 16, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Shaperon has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Shaperon in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Shaperon AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2019
2.00 KRW
Jan 1, 2020
2.00 KRW
Jan 1, 2021
2.00 KRW
Jan 1, 2022
2.00 KRW
Jan 1, 2023
2.00 KRW
Jan 1, 2024
2.00 KRW
Jan 1, 2025
2.00 KRW
The Shaperon AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shaperon Stock analysis

What does Shaperon do? Shaperon Inc is a biotechnology company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the development of pharmaceutical products targeting conditions such as atopic dermatitis, septicemia, and Alzheimer's disease. Shaperon Inc. has a workforce of 40 full-time employees. The company completed its initial public offering (IPO) on October 19, 2022, and is listed under the ticker symbol 378800.KQ with ISIN KR7378800007. Its website is http://shaperon.com/. Shaperon Inc. is engaged in research, development, manufacturing, and commercialization of therapeutic solutions for pneumonia, Alzheimer's disease, and atopic conditions, among other medicines. The company's headquarters are located in Seoul, South Korea. Shaperon Inc. operates as a publicly traded entity following its IPO in 2022, with a focus on advancing treatments for complex medical conditions through biotechnology innovation. Shaperon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shaperon stock

The AAQS of Shaperon is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Shaperon since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Shaperon

All Key Metrics — Shaperon